C5 and lupus nephritis: Thus, it provided reasonable theory for most patients with lupus nephritis-combined TMA receiving plasmapheresis treatment, and also highlighted the potential use of anti-complement bioagents like Eculizumab, the anti-C5 antibody, which was proved to be efficacious in several recent case reports in the field.51,52